Jazz Pharmaceuticals PLC (JAZZ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.39B
Last updated: Nov 17, 2026 at 4:20 PM ET
Jazz Pharmaceuticals PLC (JAZZ) Statistics
Jazz Pharmaceuticals (JAZZ) has a market cap of $15.39B and an enterprise value of $18.92B. Its share count is up 6.59% from a year earlier. Its trailing P/E of 18.5x is above its 10-year median of 10.0x.
Total Valuation
Enterprise value is 22.96% above the market cap, as debt exceeds cash.
| Market Cap | $15.39B |
|---|---|
| Enterprise Value | $18.92B |
| Latest price (Nov 17, 2026) | $240.71 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 2, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.3x and 3.7x. Its year-end P/E ranged from 5.8x to 24.1x from 2016 to 2025.
| P/E Ratio | 18.5x |
|---|---|
| Forward P/E | 15.8x |
| P/S Ratio | 3.3x |
| Forward P/S | 3.2x |
| P/B Ratio | 3.7x |
| P/FCF Ratio | 21.8x |
| P/OCF Ratio | 9.1x |
| PEG Ratio | 0.6 |
Enterprise Valuation
Counting debt and cash, the company is valued at 16.7x EBITDA and 26.8x free cash flow.
| EV / Earnings | 91.9x |
|---|---|
| EV / Sales | 4.0x |
| EV / EBITDA | 16.7x |
| EV / EBIT | 44.2x |
| EV / FCF | 26.8x |
Price Statistics
The stock is up 70.63% over 52 weeks and trades 5.11% above its 50-day average.
| Beta (1Y) | 0.70 |
|---|---|
| 52-Week Change | +70.63% |
| 1-Month Change | +15.49% |
| 3-Month Change | -4.54% |
| 6-Month Change | +1.37% |
| 5-Year Change | +62.34% |
| 10-Year Change | +97.30% |
| Total Return (1Y) | +70.63% |
| Total Return (3Y CAGR) | +25.91% |
| Total Return (5Y CAGR) | +13.07% |
| Return vs SPY (1Y) | +21.78% |
| Max Drawdown (1Y) | -21.62% |
| Max Drawdown (3Y) | -32.18% |
| Sharpe Ratio (1Y) | 0.91 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $229.00 |
| 200-Day Average | $220.77 |
| 52-Week Range | $156.95 to $266.38 |
| RSI (14 Days) | 59.7 |
| Average Volume (20 Days) | 786.47K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.82x current liabilities, and total debt is 1.33x shareholder equity.
| Current Ratio | 1.82x |
|---|---|
| Quick Ratio | 1.64x |
| Debt / Equity | 1.33x |
| Debt / EBITDA | 4.86x |
| Debt / FCF | 7.80x |
Returns and Efficiency
Return on invested capital is 3.48% over the last 12 months, against a 5-year average of 2.26%.
| Return on Equity (ROE) | 4.91% |
|---|---|
| Return on Assets (ROA) | 1.72% |
| Return on Invested Capital (ROIC) | 3.48% |
| Return on Capital Employed (ROCE) | 4.52% |
| ROE (5Y Average) | 0.19% |
| ROA (5Y Average) | 0.10% |
| ROIC (5Y Average) | 2.26% |
| Asset Turnover | 0.40x |
| Inventory Turnover | 1.15x |
| Receivables Turnover | 5.38x |
| Cash Conversion Cycle | 206 days |
Taxes
Income tax took 20.66% of pretax income over the last 12 months.
| Income Tax (TTM) | $53.66M |
|---|---|
| Effective Tax Rate | 20.66% |
Scores
JAZZ has an Altman Z-Score of 1.97, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.97 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $4.72B over the last 12 months is up 13.48% from the 12 months before.
| Revenue | $4.72B |
|---|---|
| Revenue Growth (YoY) | +13.48% |
| Gross Profit | $4.20B |
| Operating Income | $425.94M |
| Pretax Income | $259.77M |
| Net Income | $205.95M |
| EBITDA | $1.15B |
| EBIT | $427.68M |
| Reported EPS (TTM) | $13.04 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 34.92% of the $12.00B in total assets.
| Cash and Equivalents | $2.04B |
|---|---|
| Total Debt | $5.57B |
| Net Debt | $3.53B |
| Net Debt Per Share | $54.61 |
| Working Capital | $2.08B |
| Shareholder Equity | $4.19B |
| Book Value Per Share | $64.79 |
| Tangible Book Value | -$1.78B |
| Total Assets | $12.00B |
| Total Liabilities | $7.81B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $978.73M of capital spending, operating cash flow left $713.79M of free cash flow.
| Operating Cash Flow | $1.69B |
|---|---|
| Capital Expenditures | $978.73M |
| Free Cash Flow | $713.79M |
| FCF Per Share | $11.00 |
| Depreciation and Amortization | $718.57M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 9.03%, against a 5-year average of 5.27%.
| Gross Margin | 89.09% |
|---|---|
| Operating Margin | 9.03% |
| Pretax Margin | 5.51% |
| Net Margin | 4.37% |
| EBITDA Margin | 24.29% |
| EBIT Margin | 9.06% |
| FCF Margin | 15.13% |
| Gross Margin (5Y Average) | 87.38% |
| Operating Margin (5Y Average) | 5.27% |
| Net Margin (5Y Average) | -0.11% |
Growth
Revenue grew 5.26% a year over 3 years, and EPS fell 18.68% a year.
| Revenue Growth (3Y CAGR) | +5.26% |
|---|---|
| Revenue Growth (5Y CAGR) | +12.54% |
| EPS Growth (3Y CAGR) | -18.68% |
| EPS Growth (5Y CAGR) | -10.75% |
| FCF Growth (3Y CAGR) | -29.31% |
| FCF Growth (5Y CAGR) | -13.08% |
| Book Value Per Share Growth (2Y CAGR) | +14.90% |
Dividends and Yields
JAZZ does not pay a dividend. Its free cash flow yield is 4.58%.
| Earnings Yield | 5.41% |
|---|---|
| FCF Yield | 4.58% |
| Buyback Yield | 0.47% |
| Shareholder Yield | 0.47% |
Peer Position
Against 4 similar companies, JAZZ has the 3rd highest P/E.
P/E RatioPeer median 18.7x
P/S RatioPeer median 11.7x
ROICPeer median -2.58%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +68.56%
| P/E Ratio | 18.5x vs 18.7x median |
|---|---|
| P/S Ratio | 3.3x vs 11.7x median |
| ROIC | 3.48% vs -2.58% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +13.48% vs +68.56% median |
Analyst Forecast
Consensus estimates put revenue growth at 8.95% and EPS growth at 94.52% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +8.95% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +94.52% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About JAZZ
What is JAZZ's market cap?
Jazz Pharmaceuticals has a market cap of $15.39B. Its enterprise value, which adds debt and subtracts cash, is $18.92B.
What is JAZZ's P/E ratio?
Jazz Pharmaceuticals has a trailing P/E ratio of 18.5x and a forward P/E of 15.8x.
How many shares of JAZZ are outstanding?
Jazz Pharmaceuticals has 64.70M shares outstanding. The count is up 6.59% from a year earlier.
Does JAZZ pay a dividend?
No. Jazz Pharmaceuticals does not pay a dividend.
How much debt does JAZZ have?
Jazz Pharmaceuticals has $5.57B of total debt and $2.04B of cash and equivalents, a net debt position of $3.53B.
JAZZ pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts